drugset / Trial / NCT02537028
MSC2364447C Phase 1b in Systemic Lupus Erythematosus
Phase 1
Completed
24 enrolled
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The primary purpose of this Phase 1b double-blind, randomized, placebo-controlled trial is to evaluate the safety, tolerability, pharmacokinetic (PK), and biological effect of MSC2364447C administered for 4 weeks in systemic lupus erythematosus subjects (SLE).
Timeline
- Start
- 2015-11-30
- Primary completion
- 2016-10-04
- Completion
- 2016-10-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Evobrutinib | Small molecule | 25 mg | Oral |
| Subject | Evobrutinib | Small molecule | 75 mg | Oral |